Cortisol_Masthead

Board of Directors

James N Wilson

Chairman of the Board

James N. Wilson has served as a Director and as Chairman of our Board since 1999. Since 2005, he has also been the Chairman of the Board of NuGEN Technologies, Inc. (“NuGEN”), a provider of systems for genomic analysis. From 2002 to 2009, Mr Wilson served as the lead independent director of Amylin Pharmaceuticals, Inc. (“Amylin”), a publicly traded biopharmaceutical company, and from 1996 to 2001, he was Chairman of the Board of Amira Medical, Inc., which was acquired by Hoffmann-La Roche A.G. From 1991 to 1994, Mr Wilson was Chief Operating Officer of Syntex Corporation (“Syntex”), which was acquired by Roche Holding, Ltd. From 1989 to 1990, Mr Wilson was Chairman and Chief Executive Officer of Neurex Corporation (“Neurex”), which was acquired by Elan Corporation plc. From 1982 to 1988, he was Chief Executive Officer of LifeScan, Inc., which was acquired by Johnson & Johnson Company. Mr Wilson received his BA and MBA from the University of Arizona. Mr Wilson brings to our Board extensive experience in the biotechnology industry, as both a Chief Executive Officer and Director.


Joseph K Belanoff

Joseph K. Belanoff, MD, is a Co-founder of our company and has served as a member of our Board and our Chief Executive Officer since 1999, and as our President since 2014. Dr Belanoff is a clinical faculty member at Stanford University (School of Medicine), where he has, since 1992, held various positions in the Department of Psychiatry and Behavioral Sciences. Dr Belanoff received his BA from Amherst College and his MD from Columbia University’s College of Physicians & Surgeons. Dr Belanoff brings to our Board a deep knowledge of our financial activities, commercial operations, and our research and development programs. He also has valuable expertise in business administration, drug discovery, clinical medicine, and psychopharmacology.


G. Leonard Baker, Jr

G. Leonard Baker, Jr, has served as a member of our Board since 1999. Since 1973, Mr Baker has been a Managing Director of the General Partner of Sutter Hill Ventures, a venture capital firm in Palo Alto, California. Mr Baker currently serves on the boards of a number of private companies. He received his BA from Yale University and his MBA from Stanford University. Mr Baker brings to our Board extensive experience in advising companies about finance, strategic transactions, and operations.


Daniel M Bradbury

Daniel M. Bradbury has served as a member of our Board since October 2012. Mr Bradbury is the Founder and Managing Member of BioBrit, LLC, a life sciences consulting and investment firm, and Chief Executive Officer, Chairman, and Co-Founder of Equillium, Inc., a private biopharmaceutical company focused on developing first-in-class therapies to treat severe autoimmune disorders with high unmet medical need.  Mr Bradbury served as President and Chief Executive Officer of Amylin from March 2007 until its acquisition by Bristol-Myers Squibb Company in August 2012. From June 2006 until August 2012, he was a member of Amylin’s board of directors and served on its Finance and Risk Management Committee. Mr Bradbury served as Amylin’s President (2006 to 2007), Chief Operating Officer (2003 to 2006) and Executive Vice President (2000 to 2003) and held a variety of sales and marketing positions (1994 to 2003). Before joining Amylin, Mr Bradbury worked in marketing and sales for 10 years at SmithKline Beecham Pharmaceuticals. He currently serves on the boards of directors and is a member of board committees of the following publicly traded companies: Geron Corporation (Audit and Nominating & Governance Committees), Biocon Limited (Audit & Risk and Stakeholder Relation Committees) and Intercept Pharmaceuticals, Inc. (Audit and Nominating & Governance Committees). He received a Bachelor of Pharmacy from Nottingham University and a Diploma in Management Studies from Harrow and Ealing Colleges of Higher Education in the United Kingdom. Mr Bradbury brings to our Board extensive experience in pharmaceutical industry strategy, operations, and management.


Reneé D Galá

Reneé D. Galá joined our Board in June 2016. She has been the Senior Vice President and Chief Financial Officer of Theravance Biopharma, Inc., a publicly traded biopharmaceutical company, since July 2014. From 2006 to June 2014, Ms Galá held various roles in the finance organization before leading the separation of the biopharmaceutical business (now Theravance Biopharma) from the royalty company, Innoviva, Inc. From 2001 to 2006, Ms Galá held positions in global treasury, pharmaceutical sales, and corporate strategy/business development at Eli Lilly and Company, a publicly traded drug manufacturing company. Before that, Ms Galá worked for 7 years in the energy industry, both in the United States. and internationally, in positions focused on corporate finance, project finance, and mergers and acquisitions. Ms Galá received a BS in Mathematics from Vanderbilt University and an MBA from Columbia Business School. Ms Galá brings to our Board extensive experience in pharmaceutical industry sales, finance, corporate strategy, and business development.


David L Mahoney

David L. Mahoney is a private investor who has served as a member of our Board since July 2004. From 1999 to 2001, Mr Mahoney served as Co-Chief Executive Officer of McKesson HBOC, Inc., a healthcare supply management and information technology company, and as Chief Executive Officer of McKesson LLC, a healthcare management and connectivity company. He joined McKesson Corporation in 1990 as Vice President for Strategic Planning. Prior to joining McKesson, Mr Mahoney was a principal with McKinsey & Company, a management consulting firm, where he worked from 1981 to 1990. Mr Mahoney serves on the board of Symantec Corporation (“Symantec”), a publicly traded software technology company, including as chair of its Compensation Committee and a member of its Nominating and Governance Committee; and Adamas Pharmaceuticals, Inc., a publicly traded biopharmaceutical company, where he is the Lead Independent Director and chair of the Compensation Committee. Mr Mahoney also served as a member of the Audit Committee of Symantec from 2003 to 2011. He also serves on the boards of directors of the San Francisco Museum of Modern Art and Mercy Corps and is a Trustee of the Schwab/Laudus Family of Funds and Mount Holyoke College. Mr Mahoney previously served on the board of directors of KQED, Inc., a public nonprofit television and radio operator. Mr Mahoney received his BA from Princeton University and his MBA from Harvard University. Mr Mahoney brings to our Board extensive experience in pharmaceutical management, operating strategy, and logistics.


Daniel N Swisher, Jr

Daniel N. Swisher, Jr, became a member of our Board in June 2015. He has been the President and Chief Operating Officer of Jazz Pharmaceuticals since January 2018. From 2003 to December 2017, he was Chief Executive Officer and a member of the board of directors of Sunesis Pharmaceuticals, a clinical-stage biopharmaceutical company. From 2005 to 2017, he was also its President. He joined Sunesis in 2001 and had previously served as the company’s Chief Business Officer and Chief Financial Officer. Prior to that, Mr Swisher held a range of senior management roles, including Senior Vice president of Sales and Marketing at ALZA Corporation, a pharmaceutical and medical systems company, from 1992 to 2001. Mr Swisher has served as Chairman of the Board of Cerus Corporation, a publicly traded biopharmaceutical company, since 2013. Mr Swisher received his BA from Yale University and an MBA from the Stanford Graduate School of Business. Mr Swisher brings to our Board experience in life science industry sales, operations, and finance.